INTRODUCTION
Patients with rheumatoid arthritis (RA) have higher rates of morbidity and mortality than the general population, which is highly attributed to an increased risk of cardiovascular disease (CVD) among RA patients (1, 2) . The increased risk of CVD appears to be linked to coronary atherosclerosis (3, 4) and may be directly caused by chronic inflammation or secondarily caused by physical inactivity and medications used to treat RA (5) . Not surprisingly, RA treatment guidelines reflect this increased cardiovascular (CV) risk among patients with RA. Evidence-based and expert opinion-based recommendations from the European League Against Rheumatism for the screening and management of RA patients include annual CV risk assessment, management of identified CV risk factors, and aggressive suppression of the inflammatory process to further lower the CV risk (6) .
Lipid levels appear to be altered as a result of RA disease activity. Data on total cholesterol and low-density lipoprotein (LDL) cholesterol levels in patients with RA are conflicting: some studies demonstrate similar (7) or lower (8) levels of total cholesterol, whereas others demonstrate increased levels of total cholesterol and LDL cholesterol in patients with early RA (9) . Although reports on lipid profiles in RA patients vary, growing evidence suggests that patients with untreated RA have reduced total cholesterol, LDL cholesterol, and high-density lipoprotein (HDL) cholesterol levels (8, 10, 11) . Regardless of the total cholesterol changes in RA patients, several studies support the notion that RA leads to a more atherogenic lipid profile (ratio of total cholesterol to HDL cholesterol), which is correlated with disease activity and improves after treatment with antirheumatic medications (7) (8) (9) 12) .
Inflammation is a common denominator in both RA and atherosclerosis. A growing body of evidence supports the involvement of common proinflammatory cytokines, such as macrophage migration inhibitory factor, interleukin-1 (IL-1), IL-6, and tumor necrosis factor ␣ (TNF␣), in the development and progression of both RA and atherosclerosis (3, 13) . Several studies have demonstrated that the use of disease-modifying antirheumatic drugs and biologic agents that affect these cytokines reduces inflammation in patients with RA and may be associated with a reduced risk of CVD (12,14 -20) .
Given that inflammation in RA patients alters the lipid profile, it is not surprising that treatment to control inflammation in RA patients may also affect lipid levels. A recent meta-analysis of 24 observational studies evaluating the effect of TNF inhibitor therapy on lipids in patients with RA showed a small trend in an increase in total cholesterol, mostly due to an increase in HDL cholesterol levels (21) . In light of uncertainties regarding the relationship between RA, lipid profiles, and potent antiinflammatory medications such as TNF inhibitor therapy, we used a large population-based database to investigate the frequency of lipid testing in clinical practice and to explore the relationship between RA, dyslipidemia, CVD risk factors, and RA treatment. The primary objective of this study was to evaluate the proportion of RA patients receiving lipid testing and the frequency of testing compared to controls (patients with osteoarthritis [OA]). We hypothesized that patients with RA would be tested less frequently than patients with OA. Secondary objectives included comparing lipid levels in RA patients versus controls (OA patients) among patients tested for hyperlipidemia and describing changes in lipid levels in patients with RA who initiated therapy with a TNF inhibitor.
MATERIALS AND METHODS

Patient identification.
A retrospective analysis was conducted using data from the OptumInsight Impact database. This database includes medical claims, pharmacy claims, laboratory data, and patient eligibility data for 86.4 million covered patients, of which 63.7 million (74%) have pharmacy benefits and 12.6 million have laboratory results. The database includes patients ages Ն65 years, all of whom are covered by standard commercial or managed care plans. The Impact database is derived from 46 health plans located across all census regions in the US (predominantly located in the North, North Central, and Atlantic regions).
Patients were included in the study if they were age Ն18 years and had Ն2 separate physician diagnoses (Ն2 months apart) for RA ( (Table 1) . Patients were excluded from the study if they had a diagnosis for any other autoimmune inflammatory disease at any time during the study observation period (see Supplementary Table 1 , available in the online version of this article at http://online library.wiley.com/journal/10.1002/(ISSN)2151-4658). Patients with OA were chosen as a comparator group for patients with RA because OA is a chronic condition that affects joints and may limit physical functioning, but does not have the systemic inflammatory features more common to RA. Furthermore, OA patients were expected to be more comparable to RA patients, given a higher expected prevalence of use of nonsteroidal antiinflammatory drugs (a recognized CV risk factor that might impact CV risk assessment) and more frequent contact with the medical system (which can motivate more use of appropriate screening tests) compared to the general population without chronic medical conditions. Additional study eligibility requirements and study design details that varied by the 3 study objectives are listed in Table 1 .
All measures of a complete lipid panel, i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides, that occurred at any time during the observation period were evaluated in this study in time windows specific for each objective ( Table 1) . Classification of lipid levels was based on the Adult Treatment Panel III (ATP-III) cholesterol management guidelines (22) . Use of lipidlowering medications, including niacin, fibric acid derivatives, bile acid binding resins, cholesterol absorption inhibitors, and hydroxymethylglutaryl-coenzyme A reductase inhibitors, was also evaluated in this study.
Statistical analyses.
All study variables, including baseline and outcome measures, were analyzed descriptively. Dichotomous variables were expressed as numbers and percentages and continuous variables were expressed as means Ϯ SDs, medians, or percentiles.
For dichotomous variables, P values were calculated using the Mann-Whitney U test, and for continuous variables, P values were calculated using t-tests. Multivariable
Significance & Innovations
• Our retrospective analysis of a representative US database demonstrated that patients with rheumatoid arthritis (RA) are significantly less likely to be tested for hyperlipidemia than controls (patients with osteoarthritis).
• Approximately 25% of patients with RA have suboptimal low-density lipoprotein cholesterol levels according to the Adult Treatment Panel III cholesterol management guidelines.
• Initiation of anti-tumor necrosis factor therapy increased total cholesterol levels by approximately 5 mg/dl among RA patients not receiving treatment with lipid-lowering agents. tumor necrosis factor. † All objectives had a 6-month baseline period that occurred prior to the index date. ‡ Age, sex, and geographic location. § Capitated or not capitated. ¶ Individual comorbidities adjusted for include fibromyalgia, Crohn's disease, respiratory infections, diabetes mellitus, obesity, polycystic ovarian disease, coronary artery disease, heart failure, and hypertension; comorbidity scores include the Charlson Comorbidity Index and the Chronic Disease Score.
# TNF inhibitors, disease-modifying antirheumatic drugs, corticosteroids, and nonsteroidal antiinflammatory drugs. ** Bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, statins, and niacin. † † Inpatient visits, physician visits, outpatient visits, and emergency room visits. ‡ ‡ Sensitivity analyses widened the windows before and after initiating TNF inhibitor therapy to Ϯ120 days and Ϯ180 days.
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Curtis et al regression was used to control for confounders and to increase the efficiency of the estimators. The outcome variables and covariates used to control for baseline differences varied between objectives and are described in Table 1 .
RESULTS
Objective 1: frequency of lipid testing, comparing RA versus OA patients. The sample of individuals initially meeting eligibility requirements included 30,586 patients with an RA diagnosis and 107,534 patients with an OA diagnosis (control group). Characteristics of each group at baseline, defined as 6 months prior to RA or OA diagnosis, are shown in Table 2 . The groups were significantly different in most covariates; therefore, regression analysis was performed to control for these differences.
Over a median followup period of 2. ; P Ͻ 0.0001 for all comparisons), whereas HDL cholesterol levels were marginally higher for the RA cohort relative to the OA cohort (56.8 mg/dl versus 56.1 mg/ dl; P ϭ 0.02). Furthermore, significantly fewer RA patients than OA patients had borderline high or high total cholesterol and LDL cholesterol levels, based on ATP-III lipid (Figure 2 ). Mean triglyceride levels also increased in these patients (mean change 7.3 mg/dl; P ϭ 0.08). Among consistent lipid-lowering medication users (n ϭ 21), HDL cholesterol levels decreased by a mean of 3.4 mg/dl (95% CI 2.2-10.0); no significant changes were observed in total cholesterol, LDL cholesterol, and triglyceride levels (Figure 2) . The atherogenic index (ratio of total cholesterol to HDL cholesterol) decreased in both patients consistently receiving and not receiving lipid-lowering medications (3.8 to 3.6 and 3.7 to 3.6, respectively; P ϭ 0.08).
The within-person analysis described above was repeated for the groups who had lipid testing within Ϯ120 and Ϯ180 days of TNF inhibitor initiation. Study results were consistent, with adjusted LDL cholesterol levels consistently higher after TNF inhibitor initiation in patients not taking lipid-lowering medications, regardless of the timing of the test (data not shown).
DISCUSSION
This real-world analysis demonstrated that patients with RA had mean total cholesterol, LDL cholesterol, and triglyceride levels that were lower than patients with OA. Although RA patients were slightly more likely to be in a favorable ATP-III category, approximately 25% of RA patients had suboptimal lipid levels based on current ATP-III guidelines (22) . Among patients with RA initiating TNF inhibitor therapy and who had their total cholesterol and LDL cholesterol levels retested within 3 months, mean total cholesterol and LDL cholesterol levels increased by 5 and 4 mg/dl, respectively, after TNF inhibitor therapy was initiated. Finally, we observed that while patients with RA were only slightly less likely to receive any lipid testing than OA patients, approximately one-third of RA patients did not receive any testing during the observation period of more than 2 years.
Among RA patients not receiving lipid-lowering medications, we observed that treatment with a TNF inhibitor was associated with modest increases in total cholesterol and LDL cholesterol levels. This is consistent with results from other studies that observed increases in lipid levels after treatment with biologic agents. In a recent metaanalysis of 24 observational studies evaluating the effect of TNF inhibitor therapy on lipids in patients with RA, a small trend of an increase in total cholesterol was observed (21) . Of the 4 controlled studies that measured the atherogenic index, 1 study found a significant increase of 8.9% in the TNF inhibitor therapy group and a significant decrease of 10.4% in the control group (23), 2 studies reported nonsignificant decreases in the TNF inhibitor group with no changes in the control groups (24, 25) , and 1 study reported a significant decrease in cases compared to controls, but data were not provided (26) . In our study, we found minimal changes in lipid profiles among RA patients who were treated with lipid-lowering medication prior to and during TNF inhibitor therapy. However, our results could not be compared with the meta-analysis, since no similar subgroup analysis of lipid level changes among patients receiving lipid-lowering medication treatments was performed (21) .
Aside from TNF inhibitors, other biologic agents have been shown to affect lipid profiles. Tocilizumab (TCZ), which inhibits the proinflammatory cytokine IL-6 binding to its receptors (27) , is associated with decreases in inflammatory markers (28) . TCZ is associated with increased lipid levels in patients with RA (e.g., an increase in LDL cholesterol of 20 mg/dl among those receiving TCZ ϩ methotrexate), but has not been associated with an increase in CV events during short-term followup (29 -32) . In a recently completed long-term followup study of TCZ in patients with RA (mean treatment duration 2.4 years), total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride levels increased after 6 weeks of treatment and remained relatively stable at the elevated level thereafter (31, 32) .
The clinical importance of lipid levels to CVD risk in RA is not completely understood. Recent evidence suggests that there may be a paradoxical effect of lipids on the risk of CVD in RA, where lower and not higher total cholesterol and LDL cholesterol levels are associated with an increased CV risk (11) . Furthermore, although HDL cholesterol is generally considered to be cardioprotective, both through its ability to promote cholesterol efflux from artery cell walls and antiinflammatory properties that protect LDL cholesterol from oxidation, a growing body of evidence suggests that in inflammatory conditions such as RA and systemic lupus erythematosus, patients have nonprotective "proinflammatory HDL," which promotes accumulation of oxidized phospholipids in LDL cholesterol (33, 34) .
Based on what appears to be more favorable total cholesterol and LDL cholesterol distributions in RA patients compared to OA patients, the results of this analysis suggest that lipid profiles in patients with RA only partially explain the previously observed excess CVD risk associated with the systemic inflammation of RA (35) . Other inflammation-induced factors, such as increased oxidative stress, insulin resistance, endothelial dysfunction, prothrombotic state, and elevated homocysteine levels (36) , as well as noninflammatory mechanisms, such as genetic polymorphism and CV toxicity associated with certain antirheumatic drugs (e.g., glucocorticoids), may also contribute to the increased CVD risk in RA (36) .
A major strength of this study is that it is based on real-world clinical practice. The data set closely represents the US in terms of population age, sex, and geographic region (37) . Comparing the US versus the Impact data set, the age distributions are as follows: 0 -20 years (27% versus 25%), 21-39 years (27% versus 24%), 40 -64 years (31% versus 40%), and Ն65 years (13% versus 11%). In terms of regions, the distributions are as follows: Northeast (18% versus 29%), Midwest (22% versus 26%), South (37% versus 37%), and West (23% versus 11%). Similar proportions of men are in each (49% in the US versus 51% in the Impact data set).
Conclusions from this study need to be weighed within the confines of some limitations of this data source. Clinical data related to risk factors such as smoking, CVD history, family history of CVD, and blood pressure, as well as RA disease severity and activity, were not available in the database. Studies have shown that while some traditional risk factors (dyslipidemia, family cardiac history, hypertension, diabetes mellitus, and obesity) impart similar risk for a CV event among patients with or without RA, other traditional CV risk factors (male sex, smoking, and personal cardiac history) impart significantly less relative CV risk in patients with versus without RA (38) . Beyond traditional CV risk factors, several disease severity and disease activity markers in RA, such as extraarticular manifestations, elevated erythrocyte sedimentation rate, rheumatoid factor seropositivity, higher joint count, and functional status, correlate with the rate of CVD and major CV events, including myocardial infarction, congestive heart failure, and death (4,39 -41) .
Another limitation of this study is that this analysis did not investigate longitudinal changes in lipid levels associated with TNF inhibitor therapy beyond 180 days. A study by Popa et al showed that although short-term effects of TNF inhibitor therapy on lipids seemed beneficial and antiatherogenic, the atherogenic index increased after 6 months from the start of therapy. Furthermore, changes in disease activity and inflammatory status were inversely correlated with changes in total cholesterol and HDL cholesterol levels and positively correlated with the variation of atherogenic index (42) . When evaluated over a longer period of time, such as 6 months or beyond, infliximab treatment has been associated with significantly increased levels of total cholesterol and triglycerides, with no change in HDL cholesterol and LDL cholesterol or atherogenic indices at 6 months (43) . In other studies, RA patients treated with infliximab had increased lipid levels (total cholesterol, HDL cholesterol, and LDL cholesterol) initially, which returned to baseline by 6 months to 1 year of treatment (except for total cholesterol levels, which remained increased in 1 study) (26, 44) . The effect of time was partially addressed in this study by sensitivity analysis in which similar results were obtained when lipid tests were carried out before or after 120 and 180 days. However, further investigations into the long-term effect of TNF inhibitor therapy on lipid levels are needed. Finally, we excluded patients who initiated lipid-lowering therapy after initiation of TNF inhibitor therapy and before followup lipid testing was performed (i.e., described as "mixed" lipid-lowering medication users). While this may have excluded some individuals with elevated lipid levels, these patients initiated a lipid-lowering medication prior to followup lipid testing, avoiding concern for a selection bias related to the effect of TNF inhibitors on lipids.
In conclusion, patients with RA have a higher mortality rate than the general population. Much of this risk is due to CVD. This study showed that in clinical practice, RA patients were tested for dyslipidemia less frequently than their counterparts with OA. Furthermore, although patients with RA tended to have relatively lower lipid levels, more than 25% of patients had suboptimal lipid levels based on current ATP-III guidelines. Analysis of lipid levels in RA patients before and after TNF inhibitor therapy initiation showed modest increases in total cholesterol, LDL cholesterol, and HDL cholesterol levels among patients not receiving lipid-lowering medications. Due to the increased risk of CVD and mortality among patients with RA, more aggressive and earlier lipid management, including greater use of statin therapy, may be appropriate to reduce CVD among RA patients who have elevated lipid and C-reactive protein levels. Additional prospective longterm studies are needed to comprehensively determine the role of inflammation and the impact of biologic agents on lipid levels and CV outcomes in patients with RA.
